BLASOLUTIONINJECTION
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
EPYSQLI (eculizumab-aagh) by Samsung Bioepis is complement inhibitors [moa]. First approved in 2024.
Drug data last refreshed 23h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPYSQLI (eculizumab-aagh) is a monoclonal antibody complement inhibitor approved in July 2024 by Samsung Bioepis. It blocks the complement cascade to treat complement-mediated diseases. The drug is a biosimilar referencing the originator eculizumab mechanism of action.
Growth
Early-stage commercial growth trajectory as a newly approved biosimilar; team building underway for market penetration in specialty indication space.
Mechanism of Action
Complement Inhibitors
Pharmacologic Class:
Complement Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
EPYSQLI positions professionals in specialty pharma biosimilar commercialization, with emphasis on managed care negotiations, payer strategy, and specialty distribution networks. Career growth is driven by market penetration velocity and competitive differentiation in a crowded complement inhibitor space.
Brand ManagerField Sales Representative
Worked on EPYSQLI at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.